Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Study paves way for better checkpoint inhibitor response prognostication
  • News

Study paves way for better checkpoint inhibitor response prognostication

  • 22 July 2022
  • Janet Fricker
Study paves way for better checkpoint inhibitor response prognostication
Total
0
Shares
0
0
0
0
0

Use of whole exome sequencing improves prediction of response to immune checkpoint blockade (ICB). The study, published in Nature Communications, 8 July, shows incorporation of the CIRCLE tool, including new genes and pathways identified from whole exome sequencing, leads to improvements in both sensitivity and specificity.

“These results suggest that the use of broader diagnostics, such as whole exome or even whole genome sequencing, may significantly improve our ability to predict who will respond to immunotherapy – essentially showing that more data does help to better predict treatment response,” says Marcin Imieliński, the study’s senior co-author (Weill Cornell Medicine, New York).

Immune checkpoint blockade (ICB) has transformed treatment of metastatic cancer. However, unfortunately only a subset of patients respond long-term. With the cost of ICB drugs and serious side-effects associated with use, there is a need for response biomarkers. Already, biomarkers (including age, tumour type, and tumour mutational burden) are known to correlate with immunotherapy response.

In the current study, Imieliński and colleagues combined data from six previous immunotherapy studies of patients with melanoma, lung cancer, bladder cancer, and head and neck cancer. In total, the investigators were able to access data on 319 patients treated with ICB (either anti-PD-1 or anti-CTLA) for whom whole exome sequencing was available. Whole exome sequencing is a method for sequencing the part of the genome that codes for proteins (around 20,000 genes, or two percent of the genome).

In the cohort of 319 patients (using RECIST classification criteria) the team identified 14 complete responders, 80 partial responders, 47 with stable disease, and 178 with progressive disease. For the purpose of the investigation, complete and partial responders were classified as ‘responders’ and progressive disease patients as ‘non-responders’.

The team used the ‘fishHook’ model to distinguish mutations driving cancer from background mutations occurring by chance that are not involved in cancer. The approach yielded six genes with suspiciously high mutational burdens.

Next, the investigators determined if any of the six genes were enriched in people who responded or people who did not respond. They found that KRAS and BRAF were enriched in patients who responded to immunotherapy while TP53 and BCLAF1 were enriched in patients who did not respond. The team also found that certain pathways (MAPK signalling, p53 associated, and immunomodulatory) predicted response to checkpoint inhibitors.

The team then combined the four genes and three pathways with other predictive variables (age, tumour type and tumour mutational burden) to create the Cancer Immunotherapy Response CLassifiEr (CIRCLE) tool.

To validate their approach, investigators then tested the CIRCLE tool on data from 165 additional cancer patients treated with immunotherapy who had undergone whole exome sequencing. They found that, in comparison to tumour mutational burden alone, CIRCLE led to superior prediction of ICB response, with a 10.5% increase in sensitivity and an 11% increase in specificity.

“We envision that CIRCLE and more broadly the analysis of recurrently mutated cancer genes will pave the way for better prognostication tools for cancer immunotherapy,” write the authors. “While panel testing is already used routinely in immune-oncology, our results suggest that the use of broader diagnostics (including whole exome sequencing and whole genome sequencing) may significantly improve this stratification of responders and non-responders.”

In the clinical application of the CIRCLE classifier, write the authors, a practical challenge will be the need for WES [whole exome sequencing] to assess the mutation status of genes and pathways that are not commonly included on cancer gene panels (e.g. BCLAF1). “We hope that our study and other similar analyses will motivate more formal and prospective explorations into the routine clinical utility of these broader genomic assays,” they conclude.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • biomarkers
  • circle tool
  • immune checkpoint blockade
  • immunotherapy
  • prediction
  • response
  • whole exome sequencing
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Policy

A call to action: how Poland is stepping up for Ukraine’s cancer patients

  • 22 July 2022
  • Agnieszka Witkowicz-Matolicz
View Post
Next Article
  • Articles
  • Policy

Begging for imatinib: why do so many patients still lack access to this lifesaver?

  • 22 July 2022
  • Anna Wagstaff
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.